{'52WeekChange': -0.33444262,
 'SandP52WeekChange': 0.0644362,
 'address1': '955 Massachusetts Avenue',
 'address2': '4th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.95,
 'askSize': 1200,
 'averageDailyVolume10Day': 93900,
 'averageVolume': 90065,
 'averageVolume10days': 93900,
 'beta': None,
 'beta3Year': None,
 'bid': 7.5,
 'bidSize': 1100,
 'bookValue': 7.359,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 8.65,
 'dayLow': 7.94,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.896,
 'enterpriseToRevenue': 13.983,
 'enterpriseValue': 41950200,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 8.774428,
 'fiftyTwoWeekHigh': 15.95,
 'fiftyTwoWeekLow': 5.835,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10510074,
 'forwardEps': -2.86,
 'forwardPE': -2.7972028,
 'fromCurrency': None,
 'fullTimeEmployees': 63,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.01749,
 'heldPercentInstitutions': 0.72634006,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1552521600,
 'lastSplitFactor': '1:6',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/x4pharma.com',
 'longBusinessSummary': 'X4 Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the discovery, '
                        'development, and commercialization of novel '
                        'therapeutics for the treatment of primary '
                        'immune-deficiencies and cancer. Its lead drug '
                        'candidate is mavorixafor (X4P-001), an oral small '
                        'molecule antagonist of chemokine receptor CXCR4, '
                        'which is in Phase III clinical trial for the '
                        'treatment of patients with warts, '
                        'hypogammaglobulinemia, infections, and myelokathexis '
                        'syndrome; Phase Ib clinical trial to treat severe '
                        'congenital neutropenia and Waldenstr√∂m '
                        'macroglobulinemia; and Phase IIa clinical trial for '
                        'the treatment of clear cell renal cell carcinoma. The '
                        'company is also developing X4P-002 for the treatment '
                        'of glioblastoma multiforme; and X4P-003 to treat '
                        'primary immune-deficiencies. It has a license '
                        'agreement with Abbisko Therapeutics Co., Ltd. to '
                        'develop, manufacture, and commercialize mavorixafor '
                        'in combination with checkpoint inhibitors or other '
                        'agents in oncology indications. The company was '
                        'formerly known as Arsanis, Inc. and changed its name '
                        'to X4 Pharmaceuticals, Inc. in March 2019. X4 '
                        'Pharmaceuticals, Inc. was founded in 2014 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'X4 Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 129138400,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_283397098',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -53072000,
 'nextFiscalYearEnd': 1640908800,
 'open': 8.56,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857 529 8300',
 'previousClose': 8.37,
 'priceHint': 2,
 'priceToBook': 1.0871042,
 'priceToSalesTrailing12Months': 43.046135,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 8.65,
 'regularMarketDayLow': 7.94,
 'regularMarketOpen': 8.56,
 'regularMarketPreviousClose': 8.37,
 'regularMarketPrice': 8.56,
 'regularMarketVolume': 115335,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 16142300,
 'sharesPercentSharesOut': 0.012200001,
 'sharesShort': 196125,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 191747,
 'shortName': 'X4 Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0123000005,
 'shortRatio': 1.63,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'XFOR',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.296,
 'twoHundredDayAverage': 9.137518,
 'volume': 115335,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.x4pharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}